Skip to content
MarketScale
‹ Back to IndustriesHealthcare

NAVIGATING THE AGILE APPROACH TO MEDICAL PRODUCT DEVELOPMENT

Engineers love to build things! Sunrise is working to keep it that way. Traditionally, development of medical products was done using a “waterfall” development process where each phase of a project builds on the previous phase to deliver exactly what was defined in requirements up front. Agile offers a more flexible approach that maintains the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Engineers love to build things! Sunrise is working to keep it that way.

Traditionally, development of medical products was done using a “waterfall” development process where each phase of a project builds on the previous phase to deliver exactly what was defined in requirements up front. Agile offers a more flexible approach that maintains the needed medical rigor, maximizes learning, and allows requirements to evolve to a more optimum solution.

As identified in AAMI TIR45:2012, the Agile approach to Medical Product development is intended to improve development in 5 basic areas:

  • Quality
  • Productivity
  • Predictability
  • Product effectiveness
  • Safety

Quality is measured during development rather than waiting until the project is complete. The Agile methodology builds the concept of “done” into the process by requiring testing as you go. This in turn, improves on productivity as the engineers who work on the project understand before approaching a task what it means to be “done.” The engineers, on a regular basis, and regardless of the stage of development, demonstrate an operational product to the “owner”.

These frequent demonstrations improve product effectiveness as the “owner” is able to see, touch, and feel the product during the entire process. This also helps to predict when and where the project is with relation to schedule and cost.

Questions concerning product safety, clinician-backed confidence, and consumer opinion are a few of many inquiries that can direct the course of a medical product’s development. Setting strict feature sets without the ability to adjust; strict schedules without the ability to adjust; and rigid budgets without the ability to adjust can be detrimental to the end goal. As a result, Agile product development has become an increasingly popular approach to developing medical products.

The Agile methodology enhances an engineer’s fundamental thought process by:

  • Decomposing large problems into manageable tasks called stories
  • Defining “Done” for each story
  • Providing better visibility for team members, management, and the client about the progress of projects
  • Consistently building products using the same process throughout the company and with all disciplines

Agile product development is customer focused. The process encourages stakeholder and developer collaboration, and bases success on the safety and efficacy efficiency of the final product. A few ways to approach this type of project management style in the development of medical devices are:

Safety and Risk

With the needs of the end user clearly identified, the solution must be designed to solve the problem at hand without undue risk and safety exposure. Risk management activities are part of the development process, and integrating risk management into product development is critical to ensure safety and efficacy. Risk mitigations are converted into requirements, and ultimately into Agile stories and managed like any other feature. These safety requirements are decomposed into manageable tasks and put into stories.

System and Software Architecture 

System and Software development is highly iterative by nature, more so when using the agile development process. Developing robust system and software architectures during the planning phases provides a proper foundation for the subsequent design phases.

Team Synergy

Collaboration among team members is essential to ensuring that product development stays on track. Knowledge barriers can be avoided when team members are aware of the bigger picture and understand where the project is and where the project is going. Agile development encourages collaboration to break down roadblocks and spur productivity. Using Agile development across the organization helps engineers and managers to coordinate activities across disciplines including electrical and mechanical engineering.

Feedback Loop

As mentioned above, demonstrations of prototypes to stakeholders in the early phases can yield valuable feedback to improve and refine the final product before costly V&V activities commence. Required usability studies for medical products by the FDA and ISO are other more formal opportunities to gather feedback. The Agile process requires the product is operational after each step in the process, ensuring working prototypes for testing.

Sunrise Solution

Developing medical products is fun. Our goal at Sunrise is to keep it that way and make it more a more predictable process that meets the customer’s needs. The Agile methodology is a powerful tool that can be utilized in the medical product development process to allow flexibility and aid in creating improved products.

Sunrise Labs has the expertise to take innovative ideas from concept to reality. The commercial medical device industry is complex and in constant flux, therefore clients leverage our expertise to overcome design challenges while satisfying regulatory requirements. At Sunrise, our passion is improving patient outcomes by helping our clients succeed in the development of beneficial medical devices.

Learn more about Sunrise Labs, our team, services, and values today.

Read more at sunriselabs.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Direct-to-consumer telehealth raises spending, even as ASC investment surges

Direct-to-consumer telehealth raises spending, even as ASC investment surges

A Health Affairs analysis of commercial claims data (2011–13) found 12% of direct-to-consumer telehealth visits replaced visits to other providers and 88% represented new utilization, with net annual spending on acute respiratory illness increasing $45 per telehealth user. Separately, MobiHealthNews reported on August 31, 2026, via a HIMSSCast episode, that Erik Tellefson of Capital One said ambulatory surgery centers “represent one of the clearest growth structures in American healthcare.”

  • 01The most actionable benchmark for finance teams evaluating DTC telehealth is substitution rate, not visit growth. Health Affairs measured 12% substitution and 88% new utilization in commercial claims for acute respiratory illness.
  • 02The $45 per-user net annual spend increase in the Health Affairs analysis is small enough to hide in PMPM reporting but large enough to matter at scale, and it should be stress-tested against virtual-visit eligibility rules and repeat-use patterns.

Sep 2, 2026

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA named Corewell Health CFO Matthew E. Cox as its national chair effective June 1, 2026, while elevating revenue cycle and reimbursement leaders to its board, according to HFMA’s GlobeNewswire announcement. The association’s own coverage of CMS’s FY 2027 IPPS/LTCH PPS final rule summary and new Medicare cost-reporting requirements such as Worksheet S-12 indicates a compliance workload that is increasingly data- and documentation-heavy for hospital finance and reporting teams. In parallel, HFMA’s certification catalog, including the Certified Hospital Cost Report Specialist (CHCRS) and Certified Specialist Payment & Reimbursement (CSPR), points to how health systems are professionalizing the skill sets needed to operationalize reimbursement policy changes. For operators, the practical consequence shows up in staffing models, audit readiness, and the data plumbing needed to produce defensible cost reports and faster revenue cycle decisions.

  • 01HFMA’s board slate now visibly includes roles that control the work: a system CFO (Corewell Health) and a chief revenue officer overseeing $7 billion in patient revenue at Orlando Health, per GlobeNewswire. That’s a signal that cost reporting and revenue cycle execution are board-level concerns, not back-office chores.
  • 02Medicare cost reporting is moving toward more granular worksheets and documentation, and each new CMS reporting requirement becomes a data-integration project before it becomes a policy memo, per HFMA’s reporting on Worksheet S-12 and its FY 2027 IPPS/LTCH PPS coverage.
  • 03HFMA’s CHCRS, CRCR, and CSPR credentials provide a concrete way to benchmark internal capability: if cost report preparation, managed care contract terms, and prior auth workflows live in different teams, credentialing can reveal where handoffs are breaking down.

Sep 2, 2026

FDA QMSR ties supplier contracts to inspection prep

FDA QMSR ties supplier contracts to inspection prep

FDA’s Quality Management System Regulation (QMSR) took effect Feb. 2, 2026, incorporating ISO 13485:2016 into 21 CFR Part 820 and shifting inspections to a process-based model under Compliance Program 7382.850, according to MD+DI. That change is starting to show up outside the quality department: medical device OEMs are being pushed to spell out documentation, audit support, and change-control responsibilities in contract manufacturing agreements, as Medical Design and Outsourcing described. Two recent partnership moves, Ratio Therapeutics expanding radiopharmaceutical manufacturing with PharmaLogic in Idaho Falls and Menicon shifting U.S. Rose K manufacturing access to three partners after concluding a prior arrangement, illustrate how multi-party supply chains now need contract terms that map directly to integrated QMS evidence. The operational consequence is simple: under CP 7382.850, a complaint, supplier nonconformance, or process change can pull investigators across CAPA, risk management, purchasing, and design records in one thread, so contracts and quality records have to be built to travel together.

  • 01Under FDA CP 7382.850, inspection risk increasingly sits in the “handoffs” between complaint handling, CAPA, supplier controls, and the Risk Management File, so quality evidence has to be assembled end-to-end, not by department.
  • 02For OEMs outsourcing manufacturing, the most useful contract test in 2026 is whether each clause produces inspectable artifacts, who owns them, where they live, and how fast they can be produced during an audit.
  • 03Multi-partner manufacturing models, like Menicon’s three-partner Rose K availability and Ratio’s capacity expansion with PharmaLogic, raise the bar on configuration control, supplier risk classification, and change notification across sites.

Sep 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512